Common Contracts
5 similar Executive Employment Agreement contracts by Leap Therapeutics, Inc.
EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • May 15th, 2023 • Leap Therapeutics, Inc. • Pharmaceutical preparations • Massachusetts
This Executive Employment Agreement (“Agreement”) is made and entered into as of this 10th day of August, 2020 (the “Effective Date”), by and between Leap Therapeutics, Inc., a Delaware corporation (the “Company”), and Jason S. Baum (hereinafter, the “Executive”).
EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • March 12th, 2021 • Leap Therapeutics, Inc. • Pharmaceutical preparations • Massachusetts
This Executive Employment Agreement (“Agreement”) is made and entered into as of this 10th day of April, 2020, by and between Leap Therapeutics, Inc., a Delaware corporation (the “Company”), and Cynthia Sirard (hereinafter, the “Executive”).
EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • March 12th, 2021 • Leap Therapeutics, Inc. • Pharmaceutical preparations • Massachusetts
This Executive Employment Agreement (“Agreement”) is made and entered into as of this 10th day of April, 2020, by and between Leap Therapeutics, Inc., a Delaware corporation (the “Company”), and John Mark O’Mahony (hereinafter, the “Executive”).
EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • November 12th, 2020 • Leap Therapeutics, Inc. • Pharmaceutical preparations • Massachusetts
This Executive Employment Agreement (“Agreement”) is made and entered into as of this 16th day of August, 2020 (the “Effective Date”), by and between Leap Therapeutics, Inc., a Delaware corporation (the “Company”), and Christine Granfield (hereinafter, the “Executive”).
EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • April 15th, 2020 • Leap Therapeutics, Inc. • Pharmaceutical preparations • Massachusetts
This Executive Employment Agreement (“Agreement”) is made and entered into as of this 10th day of April, 2020, by and between Leap Therapeutics, Inc., a Delaware corporation (the “Company”), and Douglas E. Onsi (hereinafter, the “Executive”).
